nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Fosaprepitant—Dyspnoea—Teniposide—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Fosaprepitant—Dysuria—Vincristine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Fosaprepitant—Oedema—Fludarabine—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Fosaprepitant—Infection—Fludarabine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Fosaprepitant—Decreased appetite—Teniposide—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Fosaprepitant—Vomiting—Mechlorethamine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Fosaprepitant—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Fosaprepitant—Stomatitis—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Fosaprepitant—Urinary tract infection—Carmustine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Fosaprepitant—Rash—Mechlorethamine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Fosaprepitant—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Fosaprepitant—Weight decreased—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Fosaprepitant—Flushing—Bleomycin—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Fosaprepitant—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Fosaprepitant—Feeling abnormal—Teniposide—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Fosaprepitant—Stomatitis—Vincristine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Fosaprepitant—Nausea—Mechlorethamine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Fosaprepitant—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Fosaprepitant—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Fosaprepitant—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Fosaprepitant—Urticaria—Teniposide—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Fosaprepitant—Abdominal pain—Teniposide—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Fosaprepitant—Body temperature increased—Teniposide—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Fosaprepitant—Erythema—Bleomycin—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Fosaprepitant—Dyspnoea—Fludarabine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Fosaprepitant—Haematuria—Mitoxantrone—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Fosaprepitant—Dyspepsia—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Fosaprepitant—Dysarthria—Methotrexate—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Fosaprepitant—Decreased appetite—Fludarabine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Fosaprepitant—Fatigue—Fludarabine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Fosaprepitant—Constipation—Fludarabine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Fosaprepitant—Pain—Fludarabine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Fosaprepitant—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Fosaprepitant—Urethral disorder—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Fosaprepitant—Eye disorder—Carmustine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Fosaprepitant—Hypersensitivity—Teniposide—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Fosaprepitant—Flushing—Carmustine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Fosaprepitant—Anaemia—Bleomycin—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Fosaprepitant—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Fosaprepitant—Asthenia—Teniposide—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Fosaprepitant—Malaise—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Fosaprepitant—Pruritus—Teniposide—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Fosaprepitant—Cardiac disorder—Vincristine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Fosaprepitant—Body temperature increased—Fludarabine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Fosaprepitant—Mental disorder—Carmustine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Fosaprepitant—Malnutrition—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Fosaprepitant—Erythema—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Fosaprepitant—Cough—Bleomycin—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Fosaprepitant—Angiopathy—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Fosaprepitant—Diarrhoea—Teniposide—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Fosaprepitant—Chest pain—Bleomycin—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Fosaprepitant—Discomfort—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Fosaprepitant—Mental disorder—Vincristine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Fosaprepitant—Urine output increased—Methotrexate—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Fosaprepitant—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Fosaprepitant—Oedema—Bleomycin—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Fosaprepitant—Erythema—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Infection—Bleomycin—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Anaemia—Carmustine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Fosaprepitant—Vomiting—Teniposide—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Fosaprepitant—Asthenia—Fludarabine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Fosaprepitant—Rash—Teniposide—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Fosaprepitant—Dermatitis—Teniposide—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Fosaprepitant—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Fosaprepitant—Headache—Teniposide—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Fosaprepitant—Pruritus—Fludarabine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Fosaprepitant—Anaemia—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Fosaprepitant—Hypotension—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Fosaprepitant—Diarrhoea—Fludarabine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Fosaprepitant—Hypertension—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Nausea—Teniposide—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Anaemia—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Chest pain—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Fosaprepitant—Anxiety—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Fosaprepitant—Malaise—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Fosaprepitant—Dyspnoea—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Hypertension—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Fosaprepitant—Oedema—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Fosaprepitant—Decreased appetite—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fosaprepitant—Cough—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fosaprepitant—Infection—Carmustine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fosaprepitant—Vomiting—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Fosaprepitant—Rash—Fludarabine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Dermatitis—Fludarabine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Hypertension—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Pain—Bleomycin—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Headache—Fludarabine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Chest pain—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Fosaprepitant—Anxiety—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Fosaprepitant—Lethargy—Methotrexate—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Fosaprepitant—Discomfort—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Oedema—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Infection—Vincristine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Fosaprepitant—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Fosaprepitant—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Fosaprepitant—Nervous system disorder—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Hypotension—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Oedema—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Nausea—Fludarabine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Fosaprepitant—Infection—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Fosaprepitant—Shock—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Urticaria—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Body temperature increased—Bleomycin—lymphatic system cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Insomnia—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Skin disorder—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Hypotension—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Dyspnoea—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Somnolence—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Decreased appetite—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Hypotension—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Insomnia—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Constipation—Carmustine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Pain—Carmustine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Fosaprepitant—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Decreased appetite—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Somnolence—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Feeling abnormal—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Fatigue—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Asthenia—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Pain—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Constipation—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Pruritus—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Fatigue—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Pain—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Constipation—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Body temperature increased—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Fosaprepitant—Abdominal pain—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Abdominal pain—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Fosaprepitant—Body temperature increased—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Fosaprepitant—Urticaria—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Hypersensitivity—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Vomiting—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Fosaprepitant—Rash—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Dermatitis—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Asthenia—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Hypersensitivity—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Asthenia—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Diarrhoea—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Fosaprepitant—Nausea—Bleomycin—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Fosaprepitant—Asthenia—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Fosaprepitant—Dizziness—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Diarrhoea—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Vomiting—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Dizziness—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Rash—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Dermatitis—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Headache—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Vomiting—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Rash—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Dermatitis—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Headache—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Fosaprepitant—Nausea—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Vomiting—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Rash—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Headache—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Nausea—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Nausea—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—lymphatic system cancer	0.000995	0.000995	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00099	0.00099	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—lymphatic system cancer	0.000911	0.000911	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000885	0.000885	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—lymphatic system cancer	0.00081	0.00081	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—lymphatic system cancer	0.00081	0.00081	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000755	0.000755	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—lymphatic system cancer	0.000735	0.000735	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—lymphatic system cancer	0.000651	0.000651	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—lymphatic system cancer	0.000646	0.000646	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—lymphatic system cancer	0.000645	0.000645	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—lymphatic system cancer	0.000642	0.000642	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—lymphatic system cancer	0.000609	0.000609	CcSEcCtD
